Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 62INDUSTRY 43NIH 6NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 32Lymphoma, Follicular 13Lymphoma, Large B-Cell, Diffuse 12Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Mantle-Cell 8Burkitt Lymphoma 8Lymphoma, Non-Hodgkin 4Waldenstrom Macroglobulinemia 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Leukemia 3Lymphoma, B-Cell, Marginal Zone 2Radiation Injuries 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurotoxicity Syndromes 1Myelodysplastic Syndromes 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Immunoblastic Lymphadenopathy 1Dendritic Cell Sarcoma, Interdigitating 1Central Nervous System Neoplasms 1

Interventions

venetoclax 1tafasitamab 1glofitamab 1Rituximab 1Interviews as Topic 1Gemcitabine 1Dexamethasone 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Lymphoma, B-Cell × Rituximab × Clear all
NCT04161248 2026-05-12

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Canadian Cancer Trials Group

Phase EARLY_PHASE1 Active not recruiting
40 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡